In The News Posted December 11, 2021 Share Posted December 11, 2021 EAST HANOVER, N.J., Dec. 11, 2021 /PRNewswire/ -- Novartis today announced new 48-week data from the Phase III ASCEMBL trial of Scemblix® (asciminib) demonstrating that the results observed in the primary analysis (24 weeks) vs. Bosulif®* (bosutinib) were maintained in longer-term follow...View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now